Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.50 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CPN1 | P15169 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | PBK | Q96KB5 | 5/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 5/20 | 0.41 |
| ▸ | CDK2AP1 | O14519 | 2/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL475548 | 1.00 | SLC6A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1968950 | 1.00 | SLC6A1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL17560394 | 0.98 | SLC6A1 (0.48) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL5555738 | 0.94 | EPHX1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1469604 | 0.94 | EPHX1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL20824836 | 0.94 | EPHX1 (0.46) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 | |
| SCHEMBL1749149 | 0.87 | — | — | |
| SCHEMBL184265 | 0.87 | — | — | |
| SCHEMBL512691 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL23778361 | 0.85 | EPHX1 (0.50) | SLC6A1SLC6A11TSHRLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 614 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110372573-A | The synthesis technology of antihyperglycemic drug intermediate R-3- amino-piperadine dihydrochloride | 苏州汉德创宏生化科技有限公司 | 2019-10-25 | — | — | CN | claimed |
| CN-104926810-B | Pyrrolopyridine as kinase inhibitor | 阵列生物制药公司 | 2019-02-19 | — | — | CN | claimed |
| EP-2410855-B1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA LTD (IL) | 2016-06-01 | — | — | EP | claimed |
| WO-2016029146-A1 | SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE | UNIVERSITY OF WASHINGTON (US) | 2016-02-25 | — | — | WO | claimed |
| EP-2471775-B1 | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | SUMITOMO CHEMICAL CO (JP) | 2013-01-23 | — | — | EP | claimed |
| EP-2471775-A1 | Manufacturing method for a piperidine-3-ylcarbamate compound and optical resolution method therefor | SUMITOMO CHEMICAL CO., LTD. (JP) | 2012-07-04 | — | — | EP | claimed |
| EP-2410855-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | Mapi Pharma Limited (IL) | 2012-02-01 | — | — | EP | claimed |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-01-27 | — | — | US | claimed |
| EP-2269986-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | Sumitomo Chemical Company, Limited (JP) | 2011-01-05 | — | — | EP | claimed |
| WO-2010109468-A1 | PROCESS FOR THE PREPARATION OF ALOGLIPTIN | MAPI PHARMA HK LIMITED (CN) | 2010-09-30 | — | — | WO | claimed |
| WO-2007117482-A2 | RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-10-18 | — | — | WO | claimed |
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4665733-A1 | AMINO-SUBSTITUTED PYRROLOTRIAZINE DERIVATIVES AS INHIBITORS OF SGK1 | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12378218-B2 | Cyclopentane compounds | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| EP-4577211-A2 | PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER | Wake Forest University Health Sciences (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-1147483-C | Adamantane derivative | — | 2004-04-28 | — | — | CN | disclosed |
| US-6492355-B1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2002-12-10 | — | — | US | disclosed |
| CN-1353702-A | Adamantane derivative | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | CN | disclosed |
| EP-1171432-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000061569-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378218-B2 | Cyclopentane compounds | CYP11B2, CYP11B1, SQLE | SLC6A1 1810/4885SLC6A11 2189/4885TSHR 4152/4885 |
| US-20110021780-A1 | MANUFACTURING METHOD FOR A PIPERIDINE-3-YLCARBAMATE COMPOUND AND OPTICAL RESOLUTION METHOD THEREFOR | PDCD2L, NOTUM, OXA1L | SLC6A1 1608/4885SLC6A11 191/4885TSHR 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.